Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 76Neoplasms 71Ovarian Neoplasms 68Neoplasm Metastasis 30Fallopian Tube Neoplasms 30Carcinoma, Ovarian Epithelial 29Lung Neoplasms 26Unspecified Adult Solid Tumor, Protocol Specific 24Triple Negative Breast Neoplasms 20Endometrial Neoplasms 20Esophageal Neoplasms 18Stomach Neoplasms 16Colorectal Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Head and Neck Neoplasms 13Solid Tumors 12Small Cell Lung Carcinoma 10Melanoma 10Pancreatic Neoplasms 9Uterine Cervical Neoplasms 8Prostatic Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Carcinoma, Renal Cell 8Carcinoma 8Brenner Tumor 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

temsirolimus 1rucaparib 1niraparib 1nintedanib 1atezolizumab 1Topotecan 1Paclitaxel 1Fulvestrant 1Cell Count 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Genital Neoplasms, Female × Paclitaxel × Clear all
NCT02182245 2025-01-23

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Boehringer Ingelheim

Phase 1 Completed
22 enrolled

Genital Neoplasms, Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡